AstraZeneca, a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, agreed to acquire Alexion, a global biopharmaceutical company focused on development and commercialisation of life-changing medicines, for $39bn. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca ADSs. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients," Pascal Soriot, AstraZeneca Chief Executive Officer. On March 16, 2021, FTC clears AstraZeneca's $39bn acquisition of Alexion. On May 11, 2021, Alexion shareholders approve the $39bn acquisition by AstraZeneca. On May 25, 2021, the CMA began reviewing the merger on concerns it could reduce competition in the UK market or elsewhere. On July 14, 2021; CMA approves the $39bn AstraZeneca-Alexion deal.